Sigyn Therapeutics Files Q2 2024 10-Q

TL;DR

Sigyn Therapeutics filed its Q2 2024 10-Q, showing financial and operational details for the first half of the year.

AI Summary

Sigyn Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial information and operational updates for the company, which is involved in the Surgical & Medical Instruments & Apparatus industry. The report covers the fiscal period from January 1, 2024, to June 30, 2024, and includes comparative data from the previous year.

Why It Matters

This 10-Q filing provides investors and stakeholders with a crucial update on Sigyn Therapeutics' financial health and operational performance for the second quarter of 2024.

Risk Assessment

Risk Level: medium — As a 10-Q filing, it contains detailed financial information which can reveal significant risks or opportunities, but without specific operational details or market context, a definitive risk level is hard to assign.

Key Numbers

• 2024-06-30 — Reporting Period End Date (Indicates the end of the fiscal quarter for which financial data is reported.)
• 2024-08-19 — Filing Date (The date the 10-Q report was officially submitted to the SEC.)
• 2023-12-31 — Prior Year End Date (Provides a comparison point for financial performance from the end of the previous fiscal year.)
• 2023-06-30 — Prior Year Quarter End Date (Allows for year-over-year comparison of quarterly financial results.)

Key Players & Entities

• Sigyn Therapeutics, Inc. (company) — Filer of the 10-Q report
• 20240630 (date) — End of the reporting period
• 20240819 (date) — Date of filing
• BEVERLY HILLS, CA (location) — Company's business and mailing address
• Reign Resources Corp (company) — Former company name
• Reign Sapphire Corp (company) — Former company name

FAQ

Key Financial Figures

• $0.0001 — ction 12(g) of the Act: Common Stock, $0.0001 Par Value Indicate by check mark whet

Filing Documents

• form10-q.htm (10-Q) — 1076KB
• ex31-1.htm (EX-31.1) — 11KB
• ex31-2.htm (EX-31.2) — 7KB
• ex32-1.htm (EX-32.1) — 4KB
• ex32-2.htm (EX-32.2) — 4KB
• 0001493152-24-033048.txt ( ) — 5225KB
• sigy-20240630.xsd (EX-101.SCH) — 37KB
• sigy-20240630_cal.xml (EX-101.CAL) — 44KB
• sigy-20240630_def.xml (EX-101.DEF) — 132KB
• sigy-20240630_lab.xml (EX-101.LAB) — 337KB
• sigy-20240630_pre.xml (EX-101.PRE) — 265KB
• form10-q_htm.xml (XML) — 807KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements 4 Unaudited Condensed Consolidated Balance Sheets as of June 30, 2024 and December 31, 2023 4 Unaudited Condensed Consolidated Statements of Operations for the Three and Six months ended June 30, 2024 and 2023 5 Unaudited Condensed Consolidated Statements of Stockholders' Deficit for the Three and Six months ended June 30, 2024 and 2023 6 Unaudited Condensed Consolidated Statements of Cash Flows for the Six months ended June 30, 2024 and 2023 7 Notes to the Unaudited Condensed Consolidated Financial Statements 8 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 23 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 41 Item 4.

Controls and Procedures

Controls and Procedures 41

– OTHER INFORMATION

PART II – OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 42 Item1A.

Risk Factors

Risk Factors 42 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 42 Item 3. Defaults Upon Senior Securities 42 Item 4. Mine Safety Disclosure 42 Item 5. Other Information 42 Item 6. Exhibits 43

SIGNATURES

SIGNATURES 44 2 DISCLOSURE REGARDING FORWARD LOOKING STATEMENTS This report contains forward-looking statements. The forward-looking statements are contained principally in the sections entitled "Description of Business," "Risk Factors," and "Management's Discussion and Analysis of Financial Condition and Results of Operations." These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "anticipates," "believes," "seeks," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "would" and similar expressions intended to identify forward-looking statements. Forward-looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Sigyn to meet its financial and strategic goals, due to, among other things, competition; the ability of Sigyn to grow and manage growth profitability and retain its key employees; the possibility that the Sigyn may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Sigyn's product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected ini

View Full Filing

View this 10-Q filing on SEC EDGAR